Screener
TG Therapeutics TGTX Free cash flow margin
Discontinued — last reported Q4 '22
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from TG Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: TG Therapeutics’s 10-K, filed March 3, 2025. Open the filing →
- Filed
- Mar 3, 2025
- Fiscal year
- FY2024
- Accession
- 0001437749-25-005908
FAQ
- What is TG Therapeutics's free cash flow margin?
- TG Therapeutics (TGTX) reported free cash flow margin of -6,328.4% in Q4 2022.
- How has TG Therapeutics's free cash flow margin changed year-over-year?
- TG Therapeutics's free cash flow margin decreased by 43.0% year-over-year, from -4,425.7% to -6,328.4%.
- What is the long-term trend for TG Therapeutics's free cash flow margin?
- Over 2 years (2020 to 2022), TG Therapeutics's free cash flow margin has grown at a -78.8% compound annual growth rate (CAGR), from -141,357.9% to -6,328.4%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.
Ask your AI about TG Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude